Blood
Articles in this Issue
STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia
Abstract T-cell–recruiting bispecific antibodies (BsAbs) are in clinical development for relapsed/refractory acute myeloid leukemia (AML). Despite promising results, early clinical t...
Epigenetics-based stratification in pediatric T-ALL
GATA 2 much: stemness and resistance in AML chemotherapy
How I treat AML relapse after allogeneic HSCT
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the principal curative approaches in the treatment of acute myeloid leukemia (AML); however, relapse afte...
Luskin MR, Murakami MA, Keating J, et al. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. <i>Blood.</i> 2025;145(6):577-589.
3D insights: JAK2 46/1 haplotype shapes MPN development
CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia
Abstract Current intensive treatment of pediatric T-cell acute lymphoblastic leukemia (T-ALL) has substantial side effects, highlighting a need for novel biomarkers to improve risk s...
<i>Babesia</i> not only is invasive but creates RBC inflexibility
Clonal γδ T-cell proliferation associated with <i>Babesia</i> infection: a rare and challenging diagnostic pitfall
STING activation enhances immunotherapy of AML
From prognostication to precision in acute myeloid leukemia
The <i>JAK2</i> 46/1 haplotype influences PD-L1 expression
Abstract Although described more than a decade ago, the mechanism by which the JAK2 46/1 haplotype increases the risk of developing JAK2-mutated myeloproliferative neoplasms (MPNs) r...
EMZL at various sites: learning from each other
Abstract Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (EMZL) invariably develops from a background of chronic inflammatory disorder caused by a diverse chro...
GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia
Abstract Stemness-associated cell states are linked to chemotherapy resistance in acute myeloid leukemia (AML). We uncovered a direct mechanistic link between expression of the stem...
Hu L, Shi Y, Hsu J, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. <i>Blood</i> . 2003;101(8):3126-3135.
Lee HJ, Ramchandren R, Friedman J, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. <i>Blood.</i> 2025;145(3):290-299.
Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graft-versus-host disease
Abstract Chronic graft-versus-host disease (cGVHD) remains the leading cause of nonrelapse morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Effectiv...
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with <i>FLT3-ITD</i>–mutated AML
Abstract BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 (“MORPHO”) was a randomized study of gilteritinib compared with placebo as maintenance therapy after hemat...
Myelodysplastic neoplasm with biallelic <i>TP53</i> inactivation in a patient with plasma cell myeloma after cytotoxic therapy
Seeking an escape door from the maze of cGVHD
Babesiosis and sickle red blood cells: loss of deformability, altered osmotic fragility, and hypervesiculation
Abstract Babesiosis in sickle cell disease (SCD) is marked by severe anemia but the underlying red blood cell (RBC) rheologic parameters remain largely undefined. Here, we describe a...